tirzepatide glp-1 dosage Compare Options | Ozempic v Mounjaro | WeightWatchers Practice Nurse - Professional Resources

[DOI] [PMC free article] [PubMed] [Google Scholar] 56.Li H, Guglielmetti C, Sei YJ, Zilberter M, Le Page LM, Shields L, Yang J, Nguyen K, Tiret B, Gao X, et al

Mounjaro received FDA approval in May 2022 for adults with type 2 diabetes

Significant and sustained weight loss: Patients using Mounjaro in clinical trials have achieved substantial and lasting weight reduction, with results maximized when combined with healthy lifestyle changes

The key difference between the two medications is that Ozempic (Wegovy) is single action and mimics a hormone that targets one receptor in the body

Telehealth provider partnerships Red Rock partners with multiple telehealth platforms and weight loss clinics that can provide both the consultation and the prescription in a single workflow

A dose-dependent superiority in lowering HbA 1c was evident with all three tirzepatide doses vs all comparators, with mean differences ranging from 17.71 mmol/mol (1.62%) to 22.35 mmol/mol (2.06%) vs placebo, 3.22 mmol/mol (0.29%) to 10.06 mmol/mol (0.92%) vs GLP-1 RAs, and 7.66 mmol/mol (0.70%) to 12.02 mmol/mol (1.09%) vs basal insulin regimens